Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 30 November 2007. doi:10.1136/ard.2007.082925
Annals of the Rheumatic Diseases 2008;67:717-719
Copyright © 2008 BMJ Publishing Group Ltd & European League Against Rheumatism.

CONCISE REPORTS

Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience

L C Coates, L S Cawkwell, N W F Ng, A N Bennett, D J Bryer, A D Fraser, P Emery, H Marzo-Ortega

Academic Unit of Musculoskeletal Disease, University of Leeds and Chapel Allerton Hospital, Chapeltown Road, Leeds, UK

Professor Paul Emery, Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA; p.emery{at}leeds.ac.uk

ABSTRACT

Objective: To investigate the response to biologic drugs in psoriatic arthritis and to quantify non-response and outcome from switching agents.

Methods: 60 patients (33 men and 27 women, mean age 46 years, median disease duration 16 years) prescribed biologic drugs for psoriatic arthritis between 2001 and 2006 were studied. Response was evaluated using joint counts, C-reactive protein levels and disease activity scores (using 28 joints; DAS28).

Results: The mean percentage improvements seen were 56% in tender joint count, 70% in swollen joint count, 64% in C-reactive protein level and 36% in the overall disease activity score. Improvements were sustained beyond 24 months with no loss of effect. Side-effects leading to cessation or switching of first-line therapy were only seen in 5% of patients and non-response occurred in 20% long term. Overall, 90% of patients achieved a significant response, using switching in 20% of cases. Outcomes were similar regardless of drug used, duration of disease and subtype of arthritis.

Conclusions: Treatment of active psoriatic arthritis with anti-tumour necrosis factor agents leads to a sustained response over 3 years with most patients tolerating these drugs well. The rate of non-response is low with the majority of patients responding to second- and third-line therapies.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs